• Home
  •  / Acticor Biotech

Acticor Biotech

OverviewSuggest Edit

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke. The Company develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI.

TypePrivate
Founded2013
HQParis, FRMap
Websiteacticor-biotech.com

Recent NewsAll News

Latest Updates

Employees (est.) (Oct 2019)15(+8%)

Key People/Management at Acticor Biotech

Gilles Avenard

Gilles Avenard

CEO
Eric Cohen

Eric Cohen

CFO
Yannick Plétan

Yannick Plétan

CMO
Kristell Lebozec

Kristell Lebozec

Head of Pharmaceutical & Non-Clinical Development
Laurie Jullien

Laurie Jullien

Head of Regulatory Affairs and Quality
Show more

Acticor Biotech Office Locations

Acticor Biotech has an office in Paris
Paris, FR (HQ)
46 Rue Henri Huchard
Show all (1)

Acticor Biotech Financials and Metrics

Summary Metrics

Founding Date

2013

Acticor Biotech total Funding

$25.6 m

Acticor Biotech latest funding size

$17.66 m

Time since last funding

a year ago

Acticor Biotech investors

CapDecisif Management, Anaxago, ARMESA, Primer Capital, CapDicisif Management, Mirae Asset Financial Group, Newton Biocapital, CMS Midical Venture Investment, A&B (HK)
Acticor Biotech's latest funding round in October 2018 was reported to be $17.7 m. In total, Acticor Biotech has raised $25.6 m
Show all financial metrics

Acticor Biotech Online and Social Media Presence

Acticor Biotech's Trends

Embed Graph

Acticor Biotech Blogs

October 08, 2019

Meet us at BioJapan 2019, with Gilles Avenard, CEO of Acticor Biotech

Please join us at BioJapan 2019 Congress from October 9th-11th, 2019 and meet Gilles Avenard, CEO of Acticor Biotech.
August 09, 2019

ACT017 : un fragment d’anticorps dont l’ACTion antithrombotique est prometteuse !

Article paru dans Tribune’k Hemostase D’après la communication orale de M. Jandrot-Perrus et al., abstract OC 06.1, 27th Congress of ISTH – International Society on Thrombosis and Haemostasis 2019. Dr Caroline VAYNE, CHRU de Tours Extrait La glycoprotéine GPVI est principalement impliquée dans l’act…
July 08, 2019

ISTH 2019 Congress

July 06, 2019

ISTH Honors Five Members with Esteemed Career Awards

“The ISTH honored five individuals with the Esteemed Career Award at the ISTH 2019 Congress Opening Ceremony. These awards are presented annually to individuals whose career contributions have significantly advanced the scientific community’s understanding of diseases and disorders that affect hemos…
April 25, 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial In Arteriosclerosis, Thrombosis, and Vascular Biology; 2019; Vol 39 Issue 5; 956-964. Published on April 25th, 2019 Authors Christine Voors-Pet…
February 07, 2019

Gordon Research Conference – Cell Biology of Megakaryocytes and Platelets

Hematopoietic Stem Cells to Platelets: Roles in Hemostasis and Disease February 24 – March 1, 2019 Location:Hotel Galvez, Galveston, TX Chair: Wolfgang Bergmeier Vice Chair: Elizabeth E. Gardiner
Show more

 Acticor Biotech Frequently Asked Questions

  • When was Acticor Biotech founded?

    Acticor Biotech was founded in 2013.

  • Who are Acticor Biotech key executives?

    Acticor Biotech's key executives are Gilles Avenard, Eric Cohen and Yannick Plétan.

  • How many employees does Acticor Biotech have?

    Acticor Biotech has 15 employees.

  • Who are Acticor Biotech competitors?

    Competitors of Acticor Biotech include Seelos Therapeutics, Omeros and Albireo Pharma.

  • Where is Acticor Biotech headquarters?

    Acticor Biotech headquarters is located at 46 Rue Henri Huchard, Paris.

  • Where are Acticor Biotech offices?

    Acticor Biotech has an office in Paris.

  • How many offices does Acticor Biotech have?

    Acticor Biotech has 1 office.